COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,441 Articles (22,835 medRxiv, 8,606 bioRxiv)

Most recent first Previous |  Page 1008: Articles 10071-10080  | Next

Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent in vitro activity against the SARS-CoV-2 Omicron variant
Rosales, R., McGovern, B. L., Rodriquez, M. L., Rai, D. K., Cardin, R. D., Anderson, A. S., Sordillo, E. M., van Bakel, H., Simon, V., Garcia-Sastre, A., White, K. M.
10.1101/2022.01.17.476685 — Posted: 2022-01-19
Prediction and validation of host cleavage targets of SARS-CoV-2 3C like protease
Yucel, N., Marchiano, S., Tchelepi, E., McAfee, Q., Nimmagadda, N., Ren, A., Shi, S., Murry, C. E., Arany, Z.
10.1101/2022.01.17.476677 — Posted: 2022-01-19
Cross-sectional study to assess the efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies
Abella, E., Trigueros, M., Pradenas, E., Munoz Lopez, F., Garcia Pallarols, F., Ben Azaiz Ben Lahsen, R., Trinite, B., Urrea, V., Marfil, S., Rovirosa, C., Puig, T., Grau, E., Chamorro, A., Toledo, R., Font, M., Palacin, D., Lopez Segui, F., Carrillo, J., Prat, N., Mateu, L., Clotet, B., Blanco, J., Massanella, M.
10.1101/2022.01.19.22269531 — Posted: 2022-01-19
Serum extracellular vesicles trace COVID-19 progression and immune responses
Yim, K. H. W., Borgoni, S., Chahwan, R.
10.1101/2022.01.19.22269529 — Posted: 2022-01-19
ELF5 is a respiratory epithelial cell-specific risk gene for severe COVID-19
Pietzner, M., Chua, R. L., Wheeler, E., Jechow, K., Radbruch, H., Trump, S., Heidecker, B., Heppner, F., Eils, R., Mall, M., Sander, L. E., Lehmann, I., Lukassen, S., Wareham, N. J., Conrad, C., Langenberg, C.
10.1101/2022.01.17.22269283 — Posted: 2022-01-19
Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of Concern
Rai, D. K., Yurgelonis, I., McMonagle, P., Rothan, H. A., Hao, L., Gribenko, A., Titova, E., Kreiswirth, B., White, K. M., Zhu, Y., Anderson, A. S., Cardin, R. D.
10.1101/2022.01.17.476644 — Posted: 2022-01-19
Structural basis for Nirmatrelvir in vitro efficacy against the Omicron variant of SARS-CoV-2
Greasley, S. E., Noell, S., Plotnikova, O., Ferre, R. A., Liu, W., Bolanos, B., Fennell, K. F., Nicki, J., Craig, T., Zhu, Y., Stewart, A. E., Steppan, C. M.
10.1101/2022.01.17.476556 — Posted: 2022-01-19
Second Climate Survey of Biomedical PhD Students in the Time of Covid
Ramadoss, D., Horn, J. P.
10.1101/2022.01.13.476194 — Posted: 2022-01-18
Systematic recovery of building plumbing-associated microbial communities after extended periods of altered water demand during the COVID-19 pandemic.
Vosloo, S., Huo, L., Chauhan, U., Cotto, I., Gincley, B., Vilardi, K. J., Yoon, B., Pieper, K. J., Stubbins, A., Pinto, A. J.
10.1101/2022.01.17.22269440 — Posted: 2022-01-18
COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron
Suntronwong, N., Yorsaeng, R., Puenpa, J., Auphimai, C., Thongmee, T., Vichaiwattana, P., Kanokudom, S., Duangchinda, T., Chantima, W., Pakchotanon, P., Assawakosri, S., Nilyanimit, P., Klinfueng, S., Wongsrisang, L., Srimuan, D., Thatsanatorn, T., Sudhinaraset, N., Wanlapakorn, N., Poovorawan, Y.
10.1101/2022.01.17.22269415 — Posted: 2022-01-18

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).